Search
EU204
go.drugbank.com/drugs/DB17438InvestigationalEU204 (EBViNT) is an Epstein-Barr virus (EBV)-positive T-cell therapy currently undergoing phase 1 and 2a clinical trials in Korea for patients with EBV-positive lymphoma and solid cancer.
Oftasceine
go.drugbank.com/drugs/DB11184ApprovedIt is used in ophthalmic solutions as a staining agent when fitting soft and hard lenses. It is a fluorescent dye or luminescent agent.
Butobarbital
go.drugbank.com/drugs/DB01353ApprovedIllicitButobarbital is a sedative and a hypnotic drug.
Proxibarbal
go.drugbank.com/drugs/DB13253ApprovedProxibarbal was approved in France but was withdrawn from the market due to the risk of inducing immunoallergic thrombocytopenia [L5476].
Rocapuldencel-T
go.drugbank.com/drugs/DB17588InvestigationalRocapuldencel-T is an autologous dendritic cell immunotherapy that was investigated in NCT02662634 (A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer
Amedalin
go.drugbank.com/drugs/DB09188ExperimentalAmedalin is a selective norepinephrine reuptake inhibitor developed in the 1970s. … It has no significant effect on reuptake of serotonin and dopamine and no antihistamine or anticholinergic properties. This drug was never marketed.
Faxeladol
go.drugbank.com/drugs/DB20529InvestigationalEffect of Food on it). … Faxeladol is under investigation in clinical trial NCT03765801 (A Clinical Study in Healthy Women Which Aims to Explore the Intestinal Uptake of Two Different Tablets of GRTA9906 Into the Body and the
ADX-10061
go.drugbank.com/drugs/DB05419ExperimentalADX10061 is a potent, selective antagonist of the dopamine D1 receptor. It is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.
Oxandrolone
go.drugbank.com/drugs/DB00621ApprovedInvestigationalA synthetic hormone with anabolic and androgenic properties.
Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine
go.drugbank.com/drugs/DB15813InvestigationalSpecifically, the COVID-19 infection relies on the binding of the Spike protein to an ACEII receptor, and with the described approach, the vaccine uses these engineered minigenes to express viral proteins … As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials.